These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37166538)

  • 21. CDKL5/Stk9 kinase inactivation is associated with neuronal developmental disorders.
    Lin C; Franco B; Rosner MR
    Hum Mol Genet; 2005 Dec; 14(24):3775-86. PubMed ID: 16330482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemical genetic identification of CDKL5 substrates reveals its role in neuronal microtubule dynamics.
    Baltussen LL; Negraes PD; Silvestre M; Claxton S; Moeskops M; Christodoulou E; Flynn HR; Snijders AP; Muotri AR; Ultanir SK
    EMBO J; 2018 Dec; 37(24):. PubMed ID: 30266824
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CDKL5 deficiency in forebrain glutamatergic neurons results in recurrent spontaneous seizures.
    Wang HT; Zhu ZA; Li YY; Lou SS; Yang G; Feng X; Xu W; Huang ZL; Cheng X; Xiong ZQ
    Epilepsia; 2021 Feb; 62(2):517-528. PubMed ID: 33400301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional consequences of mutations in CDKL5, an X-linked gene involved in infantile spasms and mental retardation.
    Bertani I; Rusconi L; Bolognese F; Forlani G; Conca B; De Monte L; Badaracco G; Landsberger N; Kilstrup-Nielsen C
    J Biol Chem; 2006 Oct; 281(42):32048-56. PubMed ID: 16935860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated with severe neurodevelopmental retardation.
    Tao J; Van Esch H; Hagedorn-Greiwe M; Hoffmann K; Moser B; Raynaud M; Sperner J; Fryns JP; Schwinger E; Gécz J; Ropers HH; Kalscheuer VM
    Am J Hum Genet; 2004 Dec; 75(6):1149-54. PubMed ID: 15499549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CDKL5 protein substitution therapy rescues neurological phenotypes of a mouse model of CDKL5 disorder.
    Trazzi S; De Franceschi M; Fuchs C; Bastianini S; Viggiano R; Lupori L; Mazziotti R; Medici G; Lo Martire V; Ren E; Rimondini R; Zoccoli G; Bartesaghi R; Pizzorusso T; Ciani E
    Hum Mol Genet; 2018 May; 27(9):1572-1592. PubMed ID: 29474534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abnormalities of mitochondrial dynamics and bioenergetics in neuronal cells from CDKL5 deficiency disorder.
    Van Bergen NJ; Massey S; Stait T; Ellery M; Reljić B; Formosa LE; Quigley A; Dottori M; Thorburn D; Stroud DA; Christodoulou J
    Neurobiol Dis; 2021 Jul; 155():105370. PubMed ID: 33905871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Xp22.3 genomic deletions involving the CDKL5 gene in girls with early onset epileptic encephalopathy.
    Mei D; Marini C; Novara F; Bernardina BD; Granata T; Fontana E; Parrini E; Ferrari AR; Murgia A; Zuffardi O; Guerrini R
    Epilepsia; 2010 Apr; 51(4):647-54. PubMed ID: 19780792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CDKL5, a novel MYCN-repressed gene, blocks cell cycle and promotes differentiation of neuronal cells.
    Valli E; Trazzi S; Fuchs C; Erriquez D; Bartesaghi R; Perini G; Ciani E
    Biochim Biophys Acta; 2012; 1819(11-12):1173-85. PubMed ID: 22921766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heterozygous CDKL5 Knockout Female Mice Are a Valuable Animal Model for CDKL5 Disorder.
    Fuchs C; Gennaccaro L; Trazzi S; Bastianini S; Bettini S; Lo Martire V; Ren E; Medici G; Zoccoli G; Rimondini R; Ciani E
    Neural Plast; 2018; 2018():9726950. PubMed ID: 29977282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CDKL5 deficiency disorder: molecular insights and mechanisms of pathogenicity to fast-track therapeutic development.
    Van Bergen NJ; Massey S; Quigley A; Rollo B; Harris AR; Kapsa RMI; Christodoulou J
    Biochem Soc Trans; 2022 Aug; 50(4):1207-1224. PubMed ID: 35997111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacotherapy with sertraline rescues brain development and behavior in a mouse model of CDKL5 deficiency disorder.
    Fuchs C; Gennaccaro L; Ren E; Galvani G; Trazzi S; Medici G; Loi M; Conway E; Devinsky O; Rimondini R; Ciani E
    Neuropharmacology; 2020 May; 167():107746. PubMed ID: 31469994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CDKL5-mediated developmental tuning of neuronal excitability and concomitant regulation of transcriptome.
    Liao W; Lee KZ
    Hum Mol Genet; 2023 Nov; 32(23):3276-3298. PubMed ID: 37688574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of amphiphysin 1 as an endogenous substrate for CDKL5, a protein kinase associated with X-linked neurodevelopmental disorder.
    Sekiguchi M; Katayama S; Hatano N; Shigeri Y; Sueyoshi N; Kameshita I
    Arch Biochem Biophys; 2013 Jul; 535(2):257-67. PubMed ID: 23651931
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cell type-specific expression, regulation and compensation of CDKL5 activity in mouse brain.
    Silvestre M; Dempster K; Mihaylov SR; Claxton S; Ultanir SK
    Mol Psychiatry; 2024 Jun; 29(6):1844-1856. PubMed ID: 38326557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The three stages of epilepsy in patients with CDKL5 mutations.
    Bahi-Buisson N; Kaminska A; Boddaert N; Rio M; Afenjar A; Gérard M; Giuliano F; Motte J; Héron D; Morel MA; Plouin P; Richelme C; des Portes V; Dulac O; Philippe C; Chiron C; Nabbout R; Bienvenu T
    Epilepsia; 2008 Jun; 49(6):1027-37. PubMed ID: 18266744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HDAC4: a key factor underlying brain developmental alterations in CDKL5 disorder.
    Trazzi S; Fuchs C; Viggiano R; De Franceschi M; Valli E; Jedynak P; Hansen FK; Perini G; Rimondini R; Kurz T; Bartesaghi R; Ciani E
    Hum Mol Genet; 2016 Sep; 25(18):3887-3907. PubMed ID: 27466189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of microglia overactivation restores neuronal survival in a mouse model of CDKL5 deficiency disorder.
    Galvani G; Mottolese N; Gennaccaro L; Loi M; Medici G; Tassinari M; Fuchs C; Ciani E; Trazzi S
    J Neuroinflammation; 2021 Jul; 18(1):155. PubMed ID: 34238328
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Searching for biomarkers of CDKL5 disorder: early-onset visual impairment in CDKL5 mutant mice.
    Mazziotti R; Lupori L; Sagona G; Gennaro M; Della Sala G; Putignano E; Pizzorusso T
    Hum Mol Genet; 2017 Jun; 26(12):2290-2298. PubMed ID: 28369421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CDKL5 sculpts functional callosal connectivity to promote cognitive flexibility.
    Awad PN; Zerbi V; Johnson-Venkatesh EM; Damiani F; Pagani M; Markicevic M; Nickles S; Gozzi A; Umemori H; Fagiolini M
    Mol Psychiatry; 2024 Jun; 29(6):1698-1709. PubMed ID: 36737483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.